Aurora Cannabis (NYSE: ACB) reported Q3 revenue of C$58.4 million, versus C$73.54 million reported last year. Domestic Medical Net Revenue Steady at $26.9 Million.

"Consistent with many of our peers, the quarter presented challenges in the Canadian adult-use segment. This reinforces the importance of Aurora's broadly diversified business model that balances domestic medical, international medical, and adult-use platforms," stated Miguel Martin, Chief Executive Officer of Aurora Cannabis. "To that point, we delivered the strongest performance in domestic medical and the best results in international medical cannabis of any Canadian LP during the period. This is critical, because we expect being #1 by revenue in Canada's medical market, the largest federally regulated medical market globally, should translate into global adult-use success in the future as medical regimes evolve to adult-use markets. In addition, being the #2 largest Canadian LP by global cannabis sales this quarter, and a leader across multiple markets and segments, gives Aurora the brand recognition and clout to pursue numerous incremental opportunities around the world."

For earnings history and earnings-related data on Aurora Cannabis (ACB) click here.